Literature DB >> 6852100

Reserpine-induced locomotor stimulation in mice chronically treated with typical and atypical antidepressants.

J Maj, Z Rogóz, G Skuza, H Sowińska.   

Abstract

Previous studies have shown that chronic treatment with antidepressants (AD) leads to an increased responsiveness of NA systems to noradrenaline (NA) or its agonist. In the present paper the influence is described of a prolonged treatment with AD of different pharmacological profiles on the effect of reserpine in the first phase of its action (amine release). It has been found that in mice treated chronically (14 days, twice a day, i.p.) with imipramine, amitriptyline, maprotiline, (+)-oxaprotiline, zimelidine, citalopram, mianserin and iprindole, the injection of reserpine induces stimulation of the locomotor activity. Only (-)-oxaprotiline and fluvoxamine do not evoke this effect. AD given alone (both single and repeated doses), reserpine alone, AD in a single dose administered jointly with reserpine do not induce the locomotor stimulation. These results suggest that a prolonged treatment with AD increases the responsiveness of the dopamine (DA) mesolimbic system and/or the NA system.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6852100     DOI: 10.1016/0014-2999(83)90087-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Pharmacological properties of EXP 561, a potential antidepressant drug.

Authors:  J Maj; G Skuza; H Sowińska; G Nowak
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

2.  Reserpine augmentation of desipramine in refractory depression: clinical and neurobiological effects.

Authors:  L H Price; D S Charney; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Behavioral effects of bidirectional modulators of brain monoamines reserpine and d-amphetamine in zebrafish.

Authors:  Evan Kyzar; Adam Michael Stewart; Samuel Landsman; Christopher Collins; Michael Gebhardt; Kyle Robinson; Allan V Kalueff
Journal:  Brain Res       Date:  2013-07-01       Impact factor: 3.252

Review 4.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Alpha 2 and beta-adrenoceptor agonists modulate [3H]dopamine release from rat nucleus accumbens slices: implications for research into depression.

Authors:  B Nurse; V A Russell; J J Taljaard
Journal:  Neurochem Res       Date:  1984-09       Impact factor: 3.996

6.  Repeated treatment with imipramine potentiates the locomotor effect of apomorphine administered into the hippocampus in rats.

Authors:  A Smiałowski; J Maj
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

7.  Chronic treatment with imipramine: further functional evidence for the enhanced noradrenergic transmission in flexor reflex activity.

Authors:  J Maj; Z Górka; M Melzacka; A Rawłów; A Pilc
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-05       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.